TickerFacts.

Prelude Therapeutics Inc (PRLD): Shareholders' Equity

Annual figures by period end, from SEC filings.

$68.64M
As of 2025-12-31
$133.73M
As of 2026-06-30
-29.4%
3-year compound annual growth
-20.2%
5-year compound annual growth
$285.90M2019-12-31: -$49.41M2020-12-31: $212.18M2021-12-31: $285.90M2022-12-31: $195.44M2023-12-31: $237.09M2024-12-31: $131.46M2025-12-31: $68.64M$68.64M
2019-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$68.64M-47.8%2026-03-10, Balance as of period end
2024-12-31$131.46M-44.6%2026-03-10, Balance as of period end
2023-12-31$237.09M+21.3%2025-03-10, Balance as of period end
2022-12-31$195.44M-31.6%2024-02-15, Balance as of period end
2021-12-31$285.90M+34.7%2023-03-15, Balance as of period end
2020-12-31$212.18Mn/m2022-03-17, Balance as of period end
2019-12-31-$49.41Mn/a2021-03-16, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Prelude Therapeutics Inc (PRLD)2025-12-31$68.64M-47.8%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31-$63.61Mn/m
Jaguar Health, Inc. (JAGX)2025-12-31-$18.69Mn/m
Evommune, Inc. (EVMN)2025-12-31$205.57Mn/m
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$245.15M+75.7%
Palatin Technologies Inc (PTN)2026-06-30$6.69Mn/m
Crescent Biopharma, Inc. (CBIO)2025-12-31$203.01Mn/m
CV Sciences, Inc. (CVSI)2025-12-31$1.47M-18.2%
Pyxis Oncology, Inc. (PYXS)2025-12-31$53.41M-55.8%

Compare PRLD, EMMA, JAGX, EVMN side by side · Screen every company in Pharmaceutical Preparations ↗